Traders should monitor the upcoming April 2026 interim data readout from the ALPHA3 trial, which could serve as a major value inflection point. The extended cash runway reduces near-term dilution risk, but the lack of revenue and continued losses underscore the high-risk, binary nature of the investment ahead of clinical catalysts.
Price Chart
Executive Summary
Allogene Therapeutics reported Q4 and full-year 2025 financial results, highlighting a reduced net loss compared to the prior year and an extended cash runway into Q1 2028 due to disciplined spending and $23.7M in recovered escrow funds. The company emphasized upcoming clinical catalysts, including an interim futility analysis from its pivotal ALPHA3 trial in LBCL expected in April 2026 and proof-of-concept data from the RESOLUTION trial for ALLO-329 in autoimmune disease expected in June 2026.
Key Financial Metrics
Key Facts
- Net loss for Q4 2025 was $38.8M ($0.17/share), improved from $59.9M ($0.28/share) in Q4 2024.
- Full-year 2025 net loss was $190.9M ($0.87/share), improved from $257.6M ($1.32/share) in 2024.
- Cash, cash equivalents, and investments totaled $258.3M as of December 31, 2025, down from $373.1M in 2024.
- Cash runway extended to Q1 2028, supported by expense management and $23.7M in escrow funds recovered in February 2026.
- Guidance for 2026 operating cash expenses is ~$150M; GAAP operating expenses expected at ~$210M, including ~$35M in non-cash stock-based compensation.
- Interim futility analysis from the ALPHA3 trial (cema-cel in LBCL) expected April 2026, focusing on MRD clearance and safety.
- Initial data from the RESOLUTION trial (ALLO-329 in autoimmune disease) expected June 2026.
Financial Impact
Reduced annual net loss by $66.7 million year-over-year; cash balance decreased by $114.9 million but runway extended significantly.
Risk Factors
- Clinical trial results may not meet expectations, particularly the upcoming MRD clearance data in the ALPHA3 trial.
- Despite improved cash runway, the company remains pre-revenue and will likely require future capital raises if development programs advance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.21 (−3.20%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.21 (−38.89%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.21 (−40.39%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.21 (+42.11%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.21 (−38.58%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.21 (−44.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers